quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One

View original at finance.yahoo.com
T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One T-Mobile, Metro by T-Mobile and UScellular will offer the new iPhone 17e, which delivers incredible value with faster performance, an advanced camera system, enhanced durability, the magic of MagSafe, and double the starting storag…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • T-Mobile has the Best Mobile Network in the U.S. based on analysis of Speedtest Intelligence data from 2H 2025

    80% confidence

  • C1X cellular modem offers up to 50 percent faster cellular data performance and up to 30 percent less modem energy usage than iPad Air with M3 for active cellular users

    80% confidence

  • T-Mobile families have saved over $3,700 versus AT&T and Verizon in the past 5 years based on real monthly bill analysis

    80% confidence

  • T-Mobile offers the Best Entertainment Bundle in Wireless

    80% confidence

  • iPad Air with M4 is up to 2.3x faster than iPad Air with M1

    80% confidence

  • C1X modem is up to 2x faster than C1 in iPhone 16e and matches the speed of iPhone Air

    80% confidence

  • Ceramic Shield 2 offers 3x better scratch resistance than the previous generation and reduced glare

    80% confidence

  • T-Mobile operates America's Best Network

    80% confidence

  • iPad Air with M4 is up to 30 percent faster than iPad Air with M3

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
T-Mobile Pairs iPhone 17e and iPad Air with Plans that Bring Built-in Value from Day One — Source | Via News | pt.VIA.NEWS